Peter Kolchinsky portfolio, Q4 2025
RA Capital Management · 13F for the quarter ending Dec 31, 2025
For Q4 2025, RA Capital Management reported $9.8B across 71 US-listed positions, led by ASND (22.5%), Cidara Therapeutics Inc (7.6%) and RYTM (7.3%). Compared with its filing for Q3 2025, Peter Kolchinsky opened 21 new positions, added to 13, reduced 8 and sold out of 17; 28 positions did not change.
The largest purchase was a new position in BCRX ($123.5M); the largest sale, the sale of the whole position in 89BIO Inc ($292.4M).
Key facts
- 13F portfolio value
- $9.8BQ4 2025
- Positions
- 71
- Largest holding
- ASND 22.5%
- New positions
- 21
- Sold out
- 17
- Filed
- Feb 17, 2026
Holdings as of (Q4 2025), filed with the SEC on . Changes are measured against the filing for Sep 30, 2025. Every tracked investor's Q4 2025 13F.
Bought and sold in Q4 2025
| Stock | Move | Shares | Size | Of portfolio |
|---|---|---|---|---|
89BIO Incno ticker on file | ▼ Sold out | −19.89M | $292.4M | 3.00% |
| Climb Bio IncCLYM | ▼ Reduced 64% | −20.13M | $138.5M | 1.42% |
| BioCryst Pharmaceuticals IncBCRX | ▲ New | +15.83M | $123.5M | 1.26% |
Arcellx Incno ticker on file | ▼ Reduced 58% | −1.77M | $115.4M | 1.18% |
| Praxis Precision MedicinesPRAX | ▲ New | +373.79K | $110.2M | 1.13% |
| Rhythm Pharmaceuticals IncRYTM | ▲ Added 17% | +985.48K | $105.5M | 1.08% |
| Belite Bio IncBLTE | ▼ Reduced 51% | −442.52K | $70.8M | 0.73% |
| Olema Pharmaceuticals IncOLMA | ▲ New | +2.6M | $65M | 0.67% |
Nuvalent Incno ticker on file | ▲ Added 51% | +633.6K | $63.7M | 0.65% |
| Evommune IncEVMN | ▲ New | +3.46M | $59.2M | 0.61% |
| Vaxcyte IncPCVX | ▼ Reduced 10% | −1.24M | $57.3M | 0.59% |
| Spyre Therapeutics IncSYRE | ▲ New | +1.62M | $53.1M | 0.54% |
| Dianthus Therapeutics IncDNTH | ▼ Reduced 44% | −1.26M | $51.7M | 0.53% |
| Lexeo Therapeutics IncLXEO | ▲ New | +5M | $49.7M | 0.51% |
| Fulcrum Therapeutics IncFULC | ▼ Reduced 41% | −4.18M | $47.2M | 0.48% |
| Vor Biopharma IncVOR | ▲ Added 173% | +3.42M | $44.8M | 0.46% |
| Capricor Therapeutics IncCAPR | ▲ New | +1.51M | $43.5M | 0.45% |
| Scholar Rock Holding CorpSRRK | ▼ Sold out | −1.17M | $43.5M | 0.45% |
| Structure Therapeutics IncGPCR | ▼ Sold out | −1.52M | $42.5M | 0.44% |
| Jade Biosciences IncJBIO | ▲ Added 246% | +2.61M | $40.3M | 0.41% |
| Grail IncGRAL | ▲ New | +428.27K | $36.7M | 0.38% |
Metsera Incno ticker on file | ▼ Sold out | −675.53K | $35.4M | 0.36% |
| Disc Medicine IncIRON | ▲ Added 25% | +399.03K | $31.7M | 0.32% |
| Travere Therapeutics IncTVTX | ▼ Sold out | −1.15M | $27.5M | 0.28% |
| Benitec Biopharma IncBNTC | ▲ New | +1.85M | $24.9M | 0.26% |
| Sionna Therapeutics IncSION | ▼ Reduced 5.2% | −540.28K | $22.2M | 0.23% |
| Rezolute IncRZLT | ▲ New | +9.18M | $21.7M | 0.22% |
| Newamsterdam Pharma CompanyNAMS | ▼ Reduced 5.8% | −588.75K | $20.7M | 0.21% |
| Larimar Therapeutics IncLRMR | ▼ Sold out | −6.05M | $19.5M | 0.20% |
| Ovid Therapeutics IncOVID | ▲ New | +10.71M | $17.5M | 0.18% |
| Tango Therapeutics IncTNGX | ▼ Sold out | −2M | $16.8M | 0.17% |
| Palisade Bio IncPALI | ▲ New | +7.12M | $16.7M | 0.17% |
| Prime Medicine IncPRME | ▼ Sold out | −3M | $16.6M | 0.17% |
| Arcus Biosciences IncRCUS | ▼ Sold out | −1.14M | $15.5M | 0.16% |
| C4 Therapeutics IncCCCC | ▲ New | +8M | $15.3M | 0.16% |
| Medline IncMDLN | ▲ New | +335K | $14.1M | 0.14% |
| Uniqure NVQURE | ▼ Sold out | −200K | $11.7M | 0.12% |
| Rani Therapeutics Holdings-ARANI | ▲ New | +8.5M | $11.5M | 0.12% |
| Monopar Therapeutics IncMNPR | ▲ Added 31% | +156K | $10.2M | 0.10% |
| LB Pharmaceuticals IncLBRX | ▲ Added 24% | +431.65K | $9.6M | 0.10% |
| Design Therapeutics IncDSGN | ▲ Added 207% | +985.68K | $9.2M | 0.09% |
| Eledon Pharmaceuticals IncELDN | ▼ Sold out | −3.57M | $9.2M | 0.09% |
| CytomX Therapeutics IncCTMX | ▼ Sold out | −2.66M | $8.5M | 0.09% |
| 4D Molecular TherapeuticsFDMT | ▲ Added 24% | +1.09M | $8.2M | 0.08% |
| Surrozen IncSRZN | ▼ Sold out | −602.63K | $7.8M | 0.08% |
| Evolent Health IncEVH | ▼ Sold out | −579.05K | $4.9M | 0.05% |
| Waystar Holding CorpWAY | ▲ New | +144.4K | $4.7M | 0.05% |
| Geron CorpGERN | ▲ Added 5.6% | +3.39M | $4.5M | 0.05% |
| Glaukos CorpGKOS | ▼ Sold out | −54.18K | $4.4M | 0.05% |
| Hinge Health IncHNGE | ▲ New | +80.11K | $3.7M | 0.04% |
Exact Sciences Corpno ticker on file | ▼ Sold out | −54.94K | $3M | 0.03% |
| Inflarx NVIFRX | ▼ Sold out | −1.97M | $2.6M | 0.03% |
| Inspire Med Systems IncINSP | ▲ Added 24% | +27.06K | $2.5M | 0.03% |
| Qiagen NVQGEN | ▲ New | +43.98K | $2.1M | 0.02% |
| Orthopediatrics CorpKIDS | ▲ New | +109.96K | $2M | 0.02% |
| Health Catalyst IncHCAT | ▲ New | +793.75K | $1.9M | 0.02% |
| Palatin Technologies IncPTN | ▲ New | +70K | $1.1M | 0.01% |
| Contineum Therapeutics IncCTNM | ▲ Added 2.7% | +57.71K | $659.6K | 0.01% |
| Wave Life Sciences LtdWVE | ▲ Added 0.01% | +1K | $17K | 0.00% |
Holdings at the quarter's end
| # | Stock | Sector | Share of portfolio | Value | Shares | Reported price | Held | Since Q3 2025 |
|---|---|---|---|---|---|---|---|---|
| 1 | Ascendis Pharma A/SASND · SPONSORED ADR | Health Care | 22.5% | $2.2B | 10.28M | $213.24 | 7+ qtrs | No change |
| 2 | Cidara Therapeutics Incno ticker on file · SH | — | 7.62% | $743.4M | 3.37M | $220.89 | 6 qtrs | No change |
| 3 | Rhythm Pharmaceuticals IncRYTM | Health Care | 7.31% | $713.6M | 6.67M | $107.04 | 7+ qtrs | ▲ Added 17% |
| 4 | Avidity Biosciences Incno ticker on file · SH | — | 6.39% | $623.3M | 8.64M | $72.13 | 7+ qtrs | No change |
| 5 | Vaxcyte IncPCVX | Health Care | 5.07% | $494.8M | 10.72M | $46.14 | 7+ qtrs | ▼ Reduced 10% |
| 6 | Sionna Therapeutics IncSION | — | 4.18% | $407.5M | 9.91M | $41.14 | 4 qtrs | ▼ Reduced 5.2% |
| 7 | Newamsterdam Pharma CompanyNAMS | — | 3.43% | $335M | 9.55M | $35.08 | 7+ qtrs | ▼ Reduced 5.8% |
| 8 | Tyra Biosciences IncTYRA | — | 3.29% | $320.7M | 12.2M | $26.29 | 7+ qtrs | No change |
| 9 | Wave Life Sciences LtdWVE | — | 3.17% | $309.5M | 18.2M | $17.00 | 7+ qtrs | ▲ Added 0.01% |
| 10 | Mineralys Therapeutics IncMLYS | — | 2.72% | $265.8M | 7.32M | $36.29 | 7+ qtrs | No change |
| 11 | Edgewise Therapeutics IncEWTX | Health Care | 2.65% | $258.8M | 10.43M | $24.81 | 7+ qtrs | No change |
| 12 | Septerna IncSEPN | — | 2.00% | $195M | 7M | $27.88 | 5 qtrs | No change |
| 13 | Nuvalent Incno ticker on file | — | 1.94% | $189.1M | 1.88M | $100.59 | 2 qtrs | ▲ Added 51% |
| 14 | Disc Medicine IncIRON | — | 1.61% | $156.9M | 1.98M | $79.41 | 4 qtrs | ▲ Added 25% |
| 15 | Janux Therapeutics IncJANX | — | 1.58% | $154.4M | 11.19M | $13.80 | 7+ qtrs | No change |
| 16 | Pepgen IncPEPG | — | 1.34% | $130.6M | 20.06M | $6.51 | 7+ qtrs | No change |
| 17 | Taysha Gene Therapies IncTSHA | — | 1.33% | $129.6M | 23.56M | $5.50 | 7+ qtrs | No change |
| 18 | Ars Pharmaceuticals IncSPRY | — | 1.30% | $126.5M | 10.86M | $11.65 | 7+ qtrs | No change |
| 19 | BioCryst Pharmaceuticals IncBCRX | — | 1.27% | $123.5M | 15.83M | $7.80 | 1 qtr | New |
| 20 | Bicara Therapeutics IncBCAX | — | 1.20% | $117.1M | 6.96M | $16.83 | 6 qtrs | No change |
| 21 | Praxis Precision MedicinesPRAX | Health Care | 1.13% | $110.2M | 373.79K | $294.74 | 1 qtr | New |
| 22 | GH Research PLCGHRS | — | 1.00% | $97.5M | 7.68M | $12.70 | 7+ qtrs | No change |
| 23 | Geron CorpGERN | — | 0.86% | $84.2M | 63.77M | $1.32 | 7+ qtrs | ▲ Added 5.6% |
| 24 | Arcellx Incno ticker on file · SH | — | 0.85% | $82.6M | 1.27M | $65.20 | 7+ qtrs | ▼ Reduced 58% |
| 25 | Climb Bio IncCLYM | — | 0.80% | $77.7M | 11.29M | $6.88 | 7+ qtrs | ▼ Reduced 64% |
| 26 | Vor Biopharma IncVOR | — | 0.72% | $70.7M | 5.4M | $13.08 | 7+ qtrs | ▲ Added 173% |
| 27 | Belite Bio IncBLTE · SH | Health Care | 0.71% | $69.2M | 432.48K | $159.96 | 2 qtrs | ▼ Reduced 51% |
| 28 | Fulcrum Therapeutics IncFULC | — | 0.70% | $68.5M | 6.05M | $11.31 | 7+ qtrs | ▼ Reduced 41% |
| 29 | Lenz Therapeutics IncLENZ | — | 0.69% | $66.9M | 4.18M | $16.00 | 7+ qtrs | No change |
| 30 | Dianthus Therapeutics IncDNTH | Health Care | 0.68% | $66.4M | 1.61M | $41.21 | 7+ qtrs | ▼ Reduced 44% |
| 31 | Olema Pharmaceuticals IncOLMA | — | 0.67% | $65M | 2.6M | $25.00 | 1 qtr | New |
| 32 | Evommune IncEVMN | — | 0.61% | $59.2M | 3.46M | $17.12 | 1 qtr | New |
| 33 | Jade Biosciences IncJBIO | — | 0.58% | $56.6M | 3.67M | $15.43 | 3 qtrs | ▲ Added 246% |
| 34 | Spyre Therapeutics IncSYRE | Health Care | 0.54% | $53.1M | 1.62M | $32.76 | 1 qtr | New |
| 35 | Lexeo Therapeutics IncLXEO | — | 0.51% | $49.7M | 5M | $9.93 | 1 qtr | New |
| 36 | LB Pharmaceuticals IncLBRX | — | 0.50% | $49.2M | 2.21M | $22.26 | 2 qtrs | ▲ Added 24% |
| 37 | Monopar Therapeutics IncMNPR | — | 0.45% | $43.6M | 667.21K | $65.30 | 5 qtrs | ▲ Added 31% |
| 38 | Capricor Therapeutics IncCAPR | — | 0.45% | $43.5M | 1.51M | $28.86 | 1 qtr | New |
| 39 | 4D Molecular TherapeuticsFDMT | — | 0.43% | $42.4M | 5.65M | $7.50 | 7+ qtrs | ▲ Added 24% |
| 40 | Invivyd IncIVVD · SH | — | 0.43% | $42.3M | 17.12M | $2.47 | 2 qtrs | No change |
| 41 | Artiva Biotherapeutics IncARTV | — | 0.43% | $42.3M | 9.85M | $4.29 | 6 qtrs | No change |
| 42 | Grail IncGRAL | Health Care | 0.38% | $36.7M | 428.27K | $85.59 | 1 qtr | New |
| 43 | Assembly Biosciences IncASMB | — | 0.36% | $34.7M | 1.02M | $34.01 | 2 qtrs | No change |
| 44 | Solid Biosciences IncSLDB | — | 0.34% | $32.8M | 5.81M | $5.64 | 7+ qtrs | No change |
| 45 | Acumen Pharmaceuticals IncABOS | — | 0.32% | $31.5M | 14.93M | $2.11 | 7+ qtrs | No change |
| 46 | Benitec Biopharma IncBNTC | — | 0.26% | $24.9M | 1.85M | $13.47 | 1 qtr | New |
| 47 | Contineum Therapeutics IncCTNM | — | 0.26% | $24.9M | 2.18M | $11.43 | 2 qtrs | ▲ Added 2.7% |
| 48 | Rezolute IncRZLT | — | 0.22% | $21.7M | 9.18M | $2.36 | 1 qtr | New |
| 49 | Acrivon Therapeutics IncACRV | — | 0.21% | $20.1M | 8.34M | $2.41 | 7+ qtrs | No change |
| 50 | Nkarta IncNKTX | — | 0.21% | $20M | 10.81M | $1.85 | 7+ qtrs | No change |
| 51 | Ovid Therapeutics IncOVID | — | 0.18% | $17.5M | 10.71M | $1.63 | 1 qtr | New |
| 52 | Palisade Bio IncPALI | — | 0.17% | $16.7M | 7.12M | $2.35 | 1 qtr | New |
| 53 | Sab Biotherapeutics IncSABS | — | 0.17% | $16.5M | 4.4M | $3.74 | 2 qtrs | No change |
| 54 | C4 Therapeutics IncCCCC | — | 0.16% | $15.3M | 8M | $1.91 | 1 qtr | New |
| 55 | Medline IncMDLN · SH | Health Care | 0.14% | $14.1M | 335K | $42.00 | 1 qtr | New |
| 56 | Design Therapeutics IncDSGN | — | 0.14% | $13.7M | 1.46M | $9.38 | 2 qtrs | ▲ Added 207% |
| 57 | Inspire Med Systems IncINSP | — | 0.13% | $13.1M | 141.96K | $92.23 | 2 qtrs | ▲ Added 24% |
| 58 | Avalo Therapeutics IncAVTX | — | 0.12% | $12M | 662.97K | $18.16 | 6 qtrs | No change |
| 59 | Rani Therapeutics Holdings-ARANI | — | 0.12% | $11.5M | 8.5M | $1.35 | 1 qtr | New |
| 60 | Perceptive Cap Solutionsno ticker on file | — | 0.10% | $9.8M | 750K | $13.03 | 7+ qtrs | No change |
| 61 | Adicet Bio IncACET | — | 0.08% | $8M | 948.25K | $8.42 | 7+ qtrs | — |
| 62 | Newamsterdam Pharma Co NV-27no ticker on file · WTS | — | 0.08% | $7.7M | 333.33K | $23.00 | 7+ qtrs | No change |
| 63 | GeneDx Holdings CorpWGS | — | 0.08% | $7.5M | 58.04K | $130.06 | 3 qtrs | No change |
| 64 | Waystar Holding CorpWAY | Technology | 0.05% | $4.7M | 144.4K | $32.75 | 1 qtr | New |
| 65 | Werewolf Therapeutics IncHOWL | — | 0.04% | $4.2M | 6.68M | $0.6335 | 7+ qtrs | No change |
| 66 | Hinge Health IncHNGE | Technology | 0.04% | $3.7M | 80.11K | $46.45 | 1 qtr | New |
| 67 | Progyny IncPGNY · SH | — | 0.03% | $2.5M | 96.63K | $25.68 | 2 qtrs | No change |
| 68 | Qiagen NVQGEN · SH | Health Care | 0.02% | $2.1M | 43.98K | $47.34 | 1 qtr | New |
| 69 | Orthopediatrics CorpKIDS · SH | — | 0.02% | $2M | 109.96K | $17.76 | 1 qtr | New |
| 70 | Health Catalyst IncHCAT · SH | — | 0.02% | $1.9M | 793.75K | $2.39 | 1 qtr | New |
| 71 | Palatin Technologies IncPTN | — | 0.01% | $1.1M | 70K | $15.38 | 1 qtr | New |
By sector
| Sector | Share of portfolio | Value | Positions |
|---|---|---|---|
| Health Care | 41.1% | $4B | 11 |
| Technology | 0.09% | $8.5M | 2 |
| No sector on file | 58.8% | $5.7B | 58 |
Questions and answers
What did Peter Kolchinsky own in Q4 2025?
RA Capital Management's 13F for Q4 2025 lists 71 positions worth $9.8B. The largest: ASND (22.5%), Cidara Therapeutics Inc (7.6%), RYTM (7.3%), Avidity Biosciences Inc (6.4%), PCVX (5.1%).
What did Peter Kolchinsky buy in Q4 2025?
The largest purchases, by the shares bought at the quarter-end price the filing implies: BCRX (new, $123.5M), PRAX (new, $110.2M), RYTM (added, $105.5M), OLMA (new, $65M), Nuvalent Inc (added, $63.7M), EVMN (new, $59.2M).
What did Peter Kolchinsky sell in Q4 2025?
The largest sales: 89BIO Inc (sold out, $292.4M), CLYM (reduced, $138.5M), Arcellx Inc (reduced, $115.4M), BLTE (reduced, $70.8M), PCVX (reduced, $57.3M), DNTH (reduced, $51.7M).
When was this filing made?
RA Capital Management filed its 13F for the quarter ending Dec 31, 2025 on Feb 17, 2026. A 13F is due within 45 days of the quarter's end, so the positions were already weeks old when it became public.
Learn
Cite this page
Funkfolio, “Peter Kolchinsky portfolio, Q4 2025: RA Capital Management 13F holdings”, data as of 17 February 2026. https://funkfolio.com/gurus/peter-kolchinsky/2025-q4
Underlying data: SEC EDGAR, Form 13F-HR of RA Capital Management (CIK 1346824) for the period ending Dec 31, 2025.
Source: SEC EDGAR, Form 13F-HR for RA Capital Management (CIK 1346824), period ending Dec 31, 2025, filed Feb 17, 2026. Changes compare share counts with the filing for Sep 30, 2025; a share split in between is allowed for where one is on record. “Reported price” is a position's reported value divided by its shares. The size of a buy or sell is the change in shares at that price; a position sold out is sized at its value in the previous filing, and “of portfolio” sets the size against the $9.8B reported for this quarter. “Held” counts consecutive quarterly filings up to this one, out of the 7 looked at from here back. Sectors are those of the ranked companies on this site as they stand today. Not a live portfolio and not advice.